LC

Leslie Chong

Chief Executive Officer & Managing Director

Imugene Limited

Sydney, New South Wales


Contact Information

Email
Unlock
LinkedIn

Company Information

Company
Imugene Limited
Industry
research
Employees
40.0
Seniority
C suite
Annual Revenue
27000.0

Technologies

Amazon SES Mimecast Microsoft Office 365 WordPress.org Google Tag Manager YouTube Facebook Login (Connect) Typekit Facebook Custom Audiences Gravity Forms Mobile Friendly Apache HeapAnalytics Segment.io Google Analytics Facebook Widget Remote SharePoint

Keywords

immunooncology cancer vaccines her2 cancers mimotopes pd1 biotechnology immunotherapy biotech immune system cancer experts bcell peptide vaccines bcell bcell vaccine technology cancer therapy drug development immune checkpoint inhibitor monoclonal antibodies biotechnology research immuno-oncology car t cell therapy allogeneic therapies oncolytic virus b-cell immunotherapies cancer vaccine cd19 targeting tumor microenvironment clinical trials cancer treatment patient-centric medicine cancer stem cells monoclonal antibodies immune response activation innovative therapies cell therapy oncarlytics cf33-cd19 her-vaxx pd1-vaxx cytokine support cancer biomarkers phase 1 clinical trials tumor eradication chimeric antigen receptor autoimmune disorders transformative medicines tumor immunology safe oncolytic virus pipeline development patient access solutions cancer drug development research collaboration scientific advisory board clinical evidence fda approval orphan drug designation cancer research peer-reviewed studies biotech innovation regenerative treatment phase ii trials immunotherapies therapeutic antibodies precision medicine clinical development strategy genetically modified therapies patient quality of life treatment options pharmacodynamics health care health wellness & fitness hospital & health care

Get Full Contact Details

Subscribe to reveal email addresses and export contacts.

View Plans